Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9- tetrahydrocannabinol-tolerant rats

Journal of Neurochemistry

Volumn 74, Issue 4, 2000, Pages 1627-1635

  Di Marzo, V ^a   Berrendero, F ^b   Bisogno, T ^a   Gonzalez S ^b   Cavaliere, P ^a   Romero, J ^b,c   Cebeira, M ^b   Ramos, J A ^b   Fernandez Ruiz J J ^b  

^a CNR   (Italy)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

9 Tetrahydrocannabinol; 2 Arachidonoylglycerol; Anandamide; Cannabinoid receptor binding; Endocannabinoids; Tolerance

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR; DRONABINOL; ETHANOLAMINE DERIVATIVE; GUANOSINE TRIPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG TOLERANCE; FOREBRAIN; LIMBIC CORTEX; MALE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CANNABINOIDS; DOWN-REGULATION; ENDOCANNABINOIDS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LIMBIC SYSTEM; MALE; MARIJUANA ABUSE; MORPHOLINES; NAPHTHALENES; PHOSPHATIDYLETHANOLAMINES; POLYUNSATURATED ALKAMIDES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SULFUR RADIOISOTOPES; TETRAHYDROCANNABINOL; TRITIUM;

ANIMALIA;

EID: 0034107992     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.0741627.x     Document Type: Article

References (62)

1. 9-tetrahydrocannabinol without alteration of cannabinoid receptor binding or mRNA levels in whole brain. Pharmacol. Biochem. Behav. 46, 575-579.
2. Aceto M. D., Scates S. M., Lowe J. A., and Martin B. R. (1995) Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR141716A. Eur. J. Pharmacol. 282, R1-R2.
3. Arnone M., Maruani J., Chaperon F., Thiébot M. H., Poncelor M., Soubrié P., and Le Fur G. (1997) Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors. Pyschopharmacology 132, 104-106.
4. 9-tetrahydrocannabinol and merthiolate on acyltransferase activities in guinea pig liver microsomes. Lipids 28, 299-303.
5. Basavarajappa B. S. and Hungund B. L. (1999) Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells. J. Neurochem. 72, 522-528.
6. Basavarajappa B. S., Cooper T. B., and Hungund B. L. (1998) Chronic ethanol administration down-regulates cannabinoid receptors in mouse brain synaptic plasma membrane. Brain Res. 793, 212-218.
7. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., and Di Marzo V. (1997) Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. 322, 671-677.
8. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J. A., Fernández-Ruiz J. J., and Di Marzo V. (1999a) Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256, 377-380.
9. Bisogno T., Melck D., De Petrocellis L., and Di Marzo V. (1999b) Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. J. Neurochem. 72, 2113-2119.
10. Breivogel C. S., Sim L. J., and Childers S. R. (1997) Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 282, 1632-1642.
11. Burstein S., Budrow J., Debatis H., Hunter S. A., and Subramanian A. (1994) Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48, 1253-1264.
12. 1-cannabinoid receptors in the caudate-putamen. Mol. Brain Res. 67, 148-157.
13. De Petrocellis L., Melck D., Bisogno T., Milone A., and Di Marzo V. (1999) Finding of endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience 92, 377-387.
14. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 1946-1949.
15. Dewey W. L. (1986) Cannabinoid pharmacology. Pharmacol. Rev. 38, 151-178.
16. Di Marzo V. (1999) Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 65, 645-655.
17. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J. C., and Piomelli D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372, 686-691.
18. Di Marzo V., De Petrocellis L., Sugiura T., and Waku K. (1996) Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoylglycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227, 281-288.
19. Di Marzo V., Melck D., Bisogno T., and De Petrocellis L. (1998) Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21, 521-528.
20. Di Marzo V., Hill M. P., Bisogno T., Crossman A. R., and Brotchie J. M. (2000) Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. (in press).
21. Felder C. C., Nielsen A., Briley E. M., Palkovits M., Priller J., Axelrod J., Nguyen D. N., Richardson J. M., Riggin R. M., Koppel G. A., Paul S. M., and Becker G. W. (1996) Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393, 231-235.
22. Fontana A., Di Marzo V., Cadas H., and Piomelli D. (1995) Analysis of anandamide, an endogenous cannabinoid substance, and other natural N-acylethanolamines. Prostaglandins Leukot. Essent. Fatty Acids 53, 301-308.
23. Gardner E. L. and Vorel S. R. (1998) Cannabinoid transmission and reward-related events. Neurobiol. Dis. 5, 502-533.
24. Giuffrida A., Parsons L. H., Kerr T. M., Rodríguez de Fonseca F., Navarro M., and Piomelli D. (1999) Dopamine activation of endogenous cannabinoid signalling in dorsal striatum. Nat. Neurosci. 2, 358-363.
25. Glass M., Brotchie J., and Maneuf Y. P. (1997) Modulation of neurotransmitters by cannabinoids in the basal ganglia. Eur. J. Neurosci. 9, 199-203.
26. 9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur. J. Pharmacol. 365, 133-142.
27. Hansen H. S., Lautitzen L., Moesgaard B., Strand A. M., and Hansen H. H. (1998) Formation of N-acylphosphatidylethanolamines and N-acylethanolamines. Proposed role in neurotoxicity. Biochem. Pharmacol. 55, 719-725.
28. Hollister L. E. (1986) Health aspects of cannabis. Pharmacol. Rev. 38, 1-20.
29. 3H]-CP-55,940 binding to the cannabinoid receptor. Du Pont Biotech. Update 6, 21-27.
30. Hunter S. A. and Burstein S. H. (1997) Receptor mediation in cannabinoid-stimulated arachidonic acid mobilization and anandamide synthesis. Life Sci. 60, 1563-1573.
31. Koga D., Santa T., Fukushima T., Homma H., and Imai K. (1997) Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. 690, 7-13.
32. ++-dependent and independent mechanisms. FEBS Lett. 429, 156-165.
33. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J. F., Beslot F., Böhme G. A., Imperato A., Pedrazzini T., Roques B., Vassart G., Fratta W., and Parmentier M. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404.
34. Lowry O. H., Rosebrough N. J., Farr A. L., and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
35. Manzanares J., Corchero J., Romero J., Fernández-Ruiz, J. J., Ramos J. A., and Fuentes J. A. (1999) Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol. Sci. 20, 287-294.
36. Navarro M., Hernández E., Muñoz R. M., del Arco I., Villanua M. A., Carrera M. R., and Rodríguez de Fonseca F. (1997) Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. Neuroreport 8, 491-496.
37. Navarro M., Chowen J., Rocio A., Carrera M., del Arco I., Villanua M. A., Martin Y., Roberts A. J., Kooh G. F., and Rodríiguez de Fonseca F. (1998) CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 9, 3397-3402.
38. Nowlan R. and Cohen S. (1977) Tolerance to marijuana: heart rats and subjective "high." Clin. Pharmacol. Ther. 22, 550-556.
39. Oviedo A., Glowa J., and Herkenham M. (1993) Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. Brain Res. 616, 293-302.
40. Pertwee R. G. (1991) Tolerance and dependence on psychotropic cannabinoids. in The Biological Bases of Drug Tolerance and Dependence (Pratt J., ed), pp. 119-164. Academic Press, San Diego.
41. Pertwee R. G. (1995) Pharmacological, physiological and clinical implications of the discovery of cannabinoid receptors, in Cannabinoid Receptors (Pertwee R. G., ed), pp. 1-34. Academic Press, San Diego.
42. 9-THC inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices. Mol. Pharmacol. 40, 547-555.
43. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 47, 33-40.
44. 9-tetrahydrocannabinol. Pharmacol. Biochem. Behav. 51, 731-737.
45. Romero J., García L., Cebeira M., Zadrozny D., Fernández-Ruiz J. J., and Ramos J. A. (1995b) The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sci. 56, 2033-2040.
46. Romero J., de Miguel R., García-Palomero E., Fernández-Ruiz, J. J., and Ramos J. A. (1995c) Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Res. 694, 223-232.
47. 9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. Mol. Brain Res. 46, 100-108.
48. 9-tetrahydrocannabinol. Synapse 30, 298-308.
49. 9-tetrahydrocannabinol. J. Mol. Neurosci. 11, 109-119.
50. Romero J., de Miguel R., Ramos J. A., and Fernández-Ruiz J. J. (1998c) The activation of cannabinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci. 62, 351-363.
51. 35S]GTPγS binding and cannabinoid receptor mRNA levels in several brain structures of adult male rats chronically exposed to R-methanandamide. Neurochem. Int. 34, 473-482.
52. Rubino T., Massi P., Patrini G., Venier I., Giagnoni G., and Parolaro D. (1994) Chronic CP-55,940 alters cannabinoid receptor-mRNA in the rat brain: an in situ hybridization study. Neuroreport 5, 2493-2496.
53. Schmid P. C., Krehshach R. J., Perry S. R., Dettmer T. M., Maasson J. L., and Schmid H. H. O. (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375, 117-120.
54. Schmid H. H. O., Schmid P. C., and Natarajan V. (1996) The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids 80, 133-142.
55. 35S]GTPγS autoradiography in rat brain. J. Neurosci. 16, 8057-8066.
56. Stella N., Schweitzer P., and Piomelli D. (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature 388, 773-778.
57. 1 opioid receptor mechanism. Science 276, 2048-2050.
58. 35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol. Pharmacol. 47, 848-854.
59. 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280, R13-R15.
60. Vela G., Ruiz-Gayo M., and Fuentes J. A. (1995) Anandamide decreases naloxone-precipitated withdrawal signs in mice chronically treated with morphine. Neuropharmacology 34, 665-668.
61. 9-tetrahydrocannabinol fails to irreversibly alter brain cannabinoid receptor. Brain Res. 544, 145-149.
62. 9-tetrahydrocannabinol on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Mol. Brain Res. 62, 141-149.